1.SGK1 as a therapeutic target for central nervous system diseases.
Ya-Kang XING ; Wei LUO ; Meng-Yao FAN ; Ya-Wei TAN ; Xiao LI
Acta Physiologica Sinica 2023;75(3):451-464
Serum and glucocorticoid-regulated kinase 1 (SGK1) plays an important role in the physiological processes of hormone release, neuronal excitation and cell proliferation. SGK1 also participates in the pathophysiological processes of inflammation and apoptosis in the central nervous system (CNS). Increasing evidence demonstrates that SGK1 may serve as a target of the intervention of neurodegenerative diseases. In this article, we summarize the recent progress on the role and molecular mechanisms of SGK1 in the regulation of the function of the CNS. We also discuss the potential of newly discovered SGK1 inhibitors in the treatment of CNS diseases.
Humans
;
Cell Proliferation
;
Central Nervous System Diseases/drug therapy*
;
Inflammation
;
Protein Serine-Threonine Kinases/physiology*
2.Research progress on precious Tibetan medicine formula in prevention and treatment of central nervous system diseases.
Xiao-Min LUO ; Yi DING ; Bo-Yu ZHANG ; Cun-Ping WANG ; E ZHANG ; Rui TAN ; Pu-Yang GONG ; Jian GU
China Journal of Chinese Materia Medica 2022;47(8):2028-2037
Precious Tibetan medicine formula is a characteristic type of medicine commonly used in the clinical treatment of central nervous system diseases. Through the summary of modern research on the precious Tibetan medicine formulas such as Ratnasampil, Ershiwuwei Zhenzhu Pills, Ershiwewei Shanhu Pills, and Ruyi Zhenbao Pills, it is found that they have obvious advantages in the treatment of stroke, Alzheimer's disease, epilepsy, angioneurotic headache, and vascular dementia. Modern pharmacological studies have shown that the mechanisms of precious Tibetan medicine formulas in improving central nervous system diseases are that they promote microcirculation of brain tissue, regulate the permeability of the blood-brain barrier, alleviate inflammation, relieve oxidative stress damage, and inhibit nerve cell apoptosis. This review summarizes the clinical and pharmacological studies on precious Tibetan medicine formulas in prevention and treatment of central nervous system diseases, aiming to provide a reference for future in-depth research and innovative discovery of Tibetan medicine against central nervous diseases.
Blood-Brain Barrier
;
Brain
;
Central Nervous System Diseases
;
Humans
;
Medicine, Tibetan Traditional
;
Stroke/drug therapy*
3.Primary central nervous system lymphoma with intramedullary spinal cord involvement mimicking inflammatory demyelinating disease
Hyunsoo KIM ; Tai Seung NAM ; Michael LEVY ; Kyung Hwa LEE ; Jahae KIM ; Seung Jin LEE
Journal of Neurocritical Care 2019;12(1):55-63
BACKGROUND: Spinal cord involvement of primary central nervous system lymphoma (PCNSL) is rare in a young immunocompetent patient and can be misdiagnosed as an inflammatory demyelinating disease (IDD) of the central nervous system.
Biopsy
;
Brain
;
Central Nervous System
;
Cerebrospinal Fluid
;
Cervical Cord
;
Demyelinating Diseases
;
Drug Therapy
;
Electrons
;
Hand
;
Humans
;
Leukocytosis
;
Lymphoma
;
Magnetic Resonance Imaging
;
Medulla Oblongata
;
Methotrexate
;
Middle Aged
;
Multiple Sclerosis
;
Neuromyelitis Optica
;
Spinal Cord
4.Prescription Trends of Psychotropics in Children and Adolescents with Autism Based on Nationwide Health Insurance Data.
Minha HONG ; Seung Yup LEE ; Juhee HAN ; Jin Cheol PARK ; Yeon Jung LEE ; Ram HWANGBO ; Hyejung CHANG ; Seong Woo CHO ; Soo Young BHANG ; Bongseog KIM ; Jun Won HWANG ; Geon Ho BAHN
Journal of Korean Medical Science 2017;32(10):1687-1693
Children with autism are often medicated to manage emotional and behavioral symptoms; yet, data on such pharmacotherapy is insufficient. In this study, we investigated the Korean National Health Insurance Claims Database (NHICD) information related to autism incidence and psychotropic medication use. From the 2010–2012 NHICD, we selected a total of 31,919,732 subjects under 19 years old. To examine the diagnostic incidence, we selected patients who had at least one medical claim containing an 10th revision of International Statistical Classification of Diseases and Related Health Problems (ICD-10) code for pervasive developmental disorder, F84, not diagnosed in the previous 360 days. Psychotropics were categorized into seven classes. Then, we analyzed the data to determine the mean annual diagnostic incidence and psychotropic prescription trends. Diagnostic incidence was 17,606 for the 3 years, with a mean annual incidence per 10,000 population of 5.52. Among them, 5,348 patients were prescribed psychotropics. Atypical antipsychotics were the most commonly used, followed by antidepressants. An older age, male sex, and the availability of medical aid were associated with a higher rate of prescription than observed for a younger age, female sex, and the availability of health insurance. Psychotropic drugs were used for less than one-third of patients newly diagnosed with autism, and prescription differed by sex and age. Increased diagnostic incidence is associated with an increased prescription of psychotropic drugs. Therefore, medication-related safety data and policies for psychotropic drugs in autism should be prepared.
Adolescent*
;
Antidepressive Agents
;
Antipsychotic Agents
;
Autistic Disorder*
;
Behavioral Symptoms
;
Central Nervous System Stimulants
;
Child*
;
Drug Therapy
;
Drug Utilization
;
Female
;
Humans
;
Incidence
;
Insurance, Health*
;
International Classification of Diseases
;
Male
;
National Health Programs
;
Prescriptions*
;
Psychotropic Drugs
5.Syndrome of inappropriate antidiuretic hormone secretion following irinotecan-cisplatin administration as a treatment for recurrent ovarian clear cell carcinoma.
Do Youn KWON ; Gwan Hee HAN ; Roshani ULAK ; Kyung Do KI ; Jong Min LEE ; Seon Kyung LEE
Obstetrics & Gynecology Science 2017;60(1):115-117
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) has various causes including central nervous system disorders, pulmonary and endocrine diseases, paraneoplastic syndromes, and use of certain drugs. SIADH induced by chemotherapy with irinotecan-cisplatin is not a common complication. Here, we review a case of SIADH after treatment with irinotecan-cisplatin. A 45-year-old woman received adjuvant chemotherapy (paclitaxel-carboplatin) for ovarian clear cell carcinoma, but the cancer recurred within 9 months of chemotherapy. Subsequently, a second line of combination chemotherapy containing irinotecan-cisplatin was initiated. However, 5 days after chemotherapy administration, her general condition began to deteriorate; her hematological tests revealed hyponatremia. Therefore, it is imperative to consider the possibility of SIADH in patients being treated with irinotecan-cisplatin–based chemotherapy. Proper monitoring of serum sodium levels and assessment of clinical symptoms should be performed in such patients for early diagnosis and prompt management.
Central Nervous System Diseases
;
Chemotherapy, Adjuvant
;
Cisplatin
;
Drug Therapy
;
Drug Therapy, Combination
;
Early Diagnosis
;
Endocrine System Diseases
;
Female
;
Hematologic Tests
;
Humans
;
Hyponatremia
;
Inappropriate ADH Syndrome
;
Middle Aged
;
Paraneoplastic Syndromes
;
Sodium
6.Extracellular Vesicles in Neurodegenerative Diseases: A Double-Edged Sword.
Tissue Engineering and Regenerative Medicine 2017;14(6):667-678
Extracellular vesicles (EVs), a heterogenous group of membrane-bound particles, are virtually secreted by all cells and play important roles in cell-cell communication. Loaded with proteins, mRNAs, non-coding RNAs and membrane lipids from their donor cells, these vesicles participate in normal physiological and pathogenic processes. In addition, these subcellular vesicles are implicated in the progression of neurodegenerative disorders. Accumulating evidence suggests that intercellular communication via EVs is responsible for the propagation of key pathogenic proteins involved in the pathogenesis of amyotrophic lateral sclerosis, Parkinson's diseases, Alzheimer's diseases and other neurodegenerative disorders. For therapeutic perspective, EVs present advantage over other synthetic drug delivery systems or cell therapy; ability to cross biological barriers including blood brain barrier (BBB), ability to modulate inflammation and immune responses, stability and longer biodistribution with lack of tumorigenicity. In this review, we summarized the current state of EV research in central nervous system in terms of their values in diagnosis, disease pathology and therapeutic applications.
Amyotrophic Lateral Sclerosis
;
Blood-Brain Barrier
;
Cell- and Tissue-Based Therapy
;
Central Nervous System
;
Diagnosis
;
Drug Delivery Systems
;
Extracellular Vesicles*
;
Humans
;
Inflammation
;
Membrane Lipids
;
Neurodegenerative Diseases*
;
Pathology
;
RNA, Messenger
;
RNA, Untranslated
;
Tissue Donors
7.Neurologic Manifestations of Enterovirus 71 Infection in Korea.
Kyung Yeon LEE ; Myoung Sook LEE ; Dong Bin KIM
Journal of Korean Medical Science 2016;31(4):561-567
Enterovirus 71 frequently involves the central nervous system and may present with a variety of neurologic manifestations. Here, we aimed to describe the clinical features, magnetic resonance imaging (MRI) findings, and cerebrospinal fluid (CSF) profiles of patients presenting with neurologic complications of enterovirus 71 infection. We retrospectively reviewed the records of 31 pediatric patients hospitalized with acute neurologic manifestations accompanied by confirmed enterovirus 71 infection at Ulsan University Hospital between 2010 and 2014. The patients' mean age was 2.9 ± 5.5 years (range, 18 days to 12 years), and 80.6% of patients were less than 4 years old. Based on their clinical features, the patients were classified into 4 clinical groups: brainstem encephalitis (n = 21), meningitis (n = 7), encephalitis (n = 2), and acute flaccid paralysis (n = 1). The common neurologic symptoms included myoclonus (58.1%), lethargy (54.8%), irritability (54.8%), vomiting (48.4%), ataxia (38.7%), and tremor (35.5%). Twenty-five patients underwent an MRI scan; of these, 14 (56.0%) revealed the characteristic increased T2 signal intensity in the posterior region of the brainstem and bilateral cerebellar dentate nuclei. Twenty-six of 30 patients (86.7%) showed CSF pleocytosis. Thirty patients (96.8%) recovered completely without any neurologic deficits; one patient (3.2%) died due to pulmonary hemorrhage and shock. In the present study, brainstem encephalitis was the most common neurologic manifestation of enterovirus 71 infection. The characteristic clinical symptoms such as myoclonus, ataxia, and tremor in conjunction with CSF pleocytosis and brainstem lesions on MR images are pathognomonic for diagnosis of neurologic involvement by enterovirus 71 infection.
Acute Disease
;
Brain/diagnostic imaging
;
Central Nervous System Diseases/etiology/*pathology
;
Child
;
Child, Preschool
;
Encephalitis/pathology
;
Enterovirus A, Human/genetics/*isolation & purification
;
Enterovirus Infections/drug therapy/*pathology/virology
;
Feces/virology
;
Female
;
Humans
;
Immunoglobulins/administration & dosage
;
Infant
;
Injections, Intravenous
;
Leukocytes/cytology
;
Leukocytosis/cerebrospinal fluid/pathology
;
Magnetic Resonance Imaging
;
Male
;
RNA, Viral/genetics/metabolism
;
Real-Time Polymerase Chain Reaction
;
Republic of Korea
;
Retrospective Studies
;
Seasons
8.Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.
Hee Jung YI ; Kyung Sook HONG ; Nara MOON ; Soon Sup CHUNG ; Ryung Ah LEE ; Kwang Ho KIM
Annals of Surgical Treatment and Research 2016;90(3):179-182
5-Fluorouracil (5-FU) based chemotherapy has been commonly used to treat metastatic or advanced colon cancer as an adjuvant chemotherapy. Although the side effects of 5-FU such as gastrointestinal problems and neutropenia and thrombocytopenia are common, not many cases of 5-FU related encephalopathy are reported. Hyperammonemic encephalopathy is a rare central nervous system toxicity following 5-FU chemotherapy manifesting as altered mental status with elevated ammonia levels with no radiologic abnormality. We report one case of 5-FU induced hyperammonemic encephalopathy occurring after Folfox4 (oxaliplatin, folinic acid and 5-fluorouracil) chemotherapy in a colon cancer patient who presented with confused mental status soon after the chemotherapy and review the 5-FU related encephalopathy.
Ammonia
;
Brain Diseases, Metabolic
;
Central Nervous System
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms
;
Drug Therapy*
;
Fluorouracil*
;
Humans
;
Hyperammonemia
;
Leucovorin
;
Neutropenia
;
Thrombocytopenia
9.Diencephalic syndrome: a frequently neglected cause of failure to thrive in infants.
Ahlee KIM ; Jin Soo MOON ; Hye Ran YANG ; Ju Young CHANG ; Jae Sung KO ; Jeong Kee SEO
Korean Journal of Pediatrics 2015;58(1):28-32
PURPOSE: Diencephalic syndrome is an uncommon cause of failure to thrive in early childhood that is associated with central nervous system neoplasms in the hypothalamic-optic chiasmatic region. It is characterized by complex signs and symptoms related to hypothalamic dysfunction; such nonspecific clinical features may delay diagnosis of the brain tumor. In this study, we analyzed a series of cases in order to define characteristic features of diencephalic syndrome. METHODS: We performed a retrospective study of 8 patients with diencephalic syndrome (age, 5-38 months). All cases had presented to Seoul National University Children's Hospital between 1995 and 2013, with the chief complaint of poor weight gain. RESULTS: Diencephalic syndrome with central nervous system (CNS) neoplasm was identified in 8 patients. The mean age at which symptoms were noted was 18+/-10.5 months, and diagnosis after symptom onset was made at the mean age of 11+/-9.7 months. The mean z score was -3.15+/-1.14 for weight, -0.12+/-1.05 for height, 1.01+/-1.58 for head circumference, and -1.76+/-1.97 for weight-for-height. Clinical features included failure to thrive (n=8), hydrocephalus (n=5), recurrent vomiting (n=5), strabismus (n=2), developmental delay (n=2), hyperactivity (n=1), nystagmus (n=1), and diarrhea (n=1). On follow-up evaluation, 3 patients showed improvement and remained in stable remission, 2 patients were still receiving chemotherapy, and 3 patients were discharged for palliative care. CONCLUSION: Diencephalic syndrome is a rare cause of failure to thrive, and diagnosis is frequently delayed. Thus, it is important to consider the possibility of a CNS neoplasm as a cause of failure to thrive and to ensure early diagnosis.
Astrocytoma
;
Brain Neoplasms
;
Central Nervous System
;
Central Nervous System Neoplasms
;
Diagnosis
;
Diarrhea
;
Drug Therapy
;
Early Diagnosis
;
Failure to Thrive*
;
Follow-Up Studies
;
Head
;
Humans
;
Hydrocephalus
;
Hypothalamic Diseases
;
Infant*
;
Optic Nerve Glioma
;
Palliative Care
;
Retrospective Studies
;
Seoul
;
Strabismus
;
Vomiting
;
Weight Gain
10.Primary Histiocytic Sarcoma of the Central Nervous System.
Hoonsub SO ; Sun A KIM ; Dok Hyun YOON ; Shin Kwang KHANG ; Jihye HWANG ; Chong Hyun SUH ; Cheolwon SUH
Cancer Research and Treatment 2015;47(2):322-328
Histiocytic sarcoma is a type of lymphoma that rarely involves the central nervous system (CNS). Its rarity can easily lead to a misdiagnosis. We describe a patient with primary CNS histocytic sarcoma involving the cerebral hemisphere and spinal cord, who had been initially misdiagnosed as demyelinating disease. Two biopsies were necessary before a correct diagnosis was made. A histologic examination showed bizarre shaped histiocytes with larger nuclei and nuclear atypia. The cells were positive for CD68, CD163, and S-100 protein. As a resection was not feasible due to multifocality, he was treated with highdose methotrexate, but showed no response. As a result, he was switched to high dose cytarabine; but again, showed no response. The patient died 2 months from the start of chemotherapy and 8 months from the onset of symptoms. Since few patients with this condition have been described and histopathology is difficult to diagnose, suspicion of the disease is essential.
Biopsy
;
Central Nervous System*
;
Cerebrum
;
Cytarabine
;
Demyelinating Diseases
;
Diagnosis
;
Diagnostic Errors
;
Drug Therapy
;
Histiocytes
;
Histiocytic Sarcoma*
;
Humans
;
Lymphoma
;
Methotrexate
;
S100 Proteins
;
Sarcoma
;
Spinal Cord

Result Analysis
Print
Save
E-mail